Cyprotex PLC Strategic partnering deal with Cytocentrics
February 10 2016 - 1:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
10 February 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Strategic partnering deal signed with Cytocentrics
to offer a full package of in vitro ion channel services
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience
Contract Research Organisation, today announces the signing of a
strategic partnering deal with world leading ion channel
specialists, Cytocentrics, Inc, to extend Cyprotex's capabilities
in the in vitro ion channel screening market. As part of the
agreement, Cytocentrics will provide equipment, cell lines,
expertise and training to allow Cyprotex to provide a panel of
different ion channel assays from its Watertown site, near Boston
in the USA.
A consortium in the USA known as CiPA (Comprehensive in Vitro
Proarrythmia Assay) is currently evaluating a new paradigm for
regulatory cardiac safety testing using in silico and in vitro
methods. CiPA is co-sponsored by the Cardiac Safety Research
Consortium (CSRC), the Health and Environmental Sciences Institute
(HESI) and the US Food and Drug Administration (FDA). The in vitro
methods currently being evaluated include single ion channels
measurements, and integrated ion channel measurements in human stem
cell-derived cardiomyocytes. Cyprotex is an active member of CiPA
and plays a vital role in the development and validation of the
human stem-cell derived cardiomyocyte assays using microelectrode
array. This is an area in which Cyprotex has considerable expertise
being the first company to launch this technology onto the market
as a higher throughput platform via its eCiphr(R) Cardio service.
The Cytocentrics agreement will complement existing technology
already provided by Cyprotex by allowing Cyprotex to offer a panel
of single ion channel measurements. This will enable Cyprotex to
offer a fully comprehensive package of in vitro cardiac safety
services which focus on key testing methods currently being
addressed within the CiPA initiative.
The introduction of the new ion channel services will not only
allow Cyprotex to offer cardiac safety testing but will also allow
screening for potential biological effects on ion channels and so
will extend Cyprotex's bioscience capabilities. The new facility,
anticipated to be operational in H1 2016, is expected to contribute
to the Company's performance from H2 2016 in line with current
market expectations. The new services will utilise Cytocentrics
CytoPatch(TM) 4 instruments and stably transfected cell lines. The
CytoPatch(TM) 4 is an automated patch clamp system which uses a
quartz glass pipette analogous to manual patch clamp and allows
robust gigaseal recordings.
Anthony Baxter PhD, Chief Executive Officer of Cyprotex,
comments on the agreement, 'Regulatory cardiac safety testing for
new pharmaceuticals is expected to change in the near future with a
greater focus on in vitro and in silico methods. Cyprotex is well
placed to address this trend and will have the capability to offer
a comprehensive package of in vitro cardiac services through its
existing offerings and through our new partnership with
Cytocentrics.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1300 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, please visit www.cyprotex.com.
About Cytocentrics, Inc.
Cytocentrics is a leading provider of ion channel services and
equipment. The Company's core capabilities include CiPA ion channel
panel screening (GLP and non-GLP), ion channel screening with
native and iPS human cardiac myocytes, action potential assays with
native and iPS human cardiac myocytes, high-throughput contractile
force assays using iPS cardiac myocytes, and production and sales
of high quality "hands-free" patch clamp equipment. Cytocentrics is
proud to have been contracted by the FDA to provide CiPA ion
channel screening as well as the CytoPatch(TM) 4 platform. In
addition, through a strategic alliance with Axiogenesis,
Cytocentrics has exclusive rights to the next generation of human
matured iPS cells which look and behave like native adult
cardiomyocytes. This development leap provides the opportunity to
examine compound effects on electrophysiology using patch clamp and
MEA platforms, and contractile force using our high throughput
platform. For more information, please visit
www.cytocentrics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADKLFBQLFXBBV
(END) Dow Jones Newswires
February 10, 2016 02:00 ET (07:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024